111, Inc. has announced the appointment of independent financial and legal advisors to review a strategic proposal. This decision comes as the company navigates its ongoing transformation into a tech-enabled healthcare platform. The move is significant for 111, Inc. as it seeks to enhance its operations and explore potential opportunities in the competitive retail-drug sector.
According to the filing dated October 26, 2026, the company has established a special committee comprising three independent directors to oversee the evaluation process. The committee includes Mr. Jian Sun, who serves as the chairman, along with Mr. Nee Chuan Teo and Mr. Jun Luo. The committee has retained Houlihan Lokey China Limited as its independent financial advisor and Kirkland & Ellis as its U.S. legal counsel.
This strategic move is part of 111, Inc.'s broader efforts to assess a previously announced preliminary, non-binding proposal letter dated September 16, 2026. The proposal aims to explore various strategic alternatives that the company may pursue.
111, Inc. operates in the retail-drug stores and proprietary stores sector, as classified under SIC 5912. The company's recent actions reflect a growing trend in the industry, where companies are increasingly seeking to enhance their strategic positions through evaluations and potential restructuring.
In the filing, the Board of Directors cautioned shareholders and others considering trading the company's securities that no decisions have been made regarding the proposal or any alternative strategic options. The Board emphasized that there is no assurance that any definitive offer will be received or that any definitive agreement will be executed relating to the transaction contemplated by the proposal.
111, Inc. is known for its technology-enabled healthcare platform that connects consumers, pharmacies, and pharmaceutical companies. The company aims to make healthcare products and services more accessible and efficient through digitalization and artificial intelligence.
The filing does not specify what happens next in the evaluation process, leaving the door open for various future developments. As 111, Inc. continues its transformation, other companies in the retail-drug sector may be inspired to follow suit in exploring strategic alternatives.